HB1532 would amend the Federal Food, Drug, and Cosmetic Act to establish externally led, science-focused drug development meetings (EL–SFDD meetings) aimed at addressing science-related challenges in rare disease drug development. The Reagan-Udall Foundation would convene these meetings, with at least four events each year, and a multistakeholder steering committee to guide topics and speaker selection.
The bill also requires FDA participation, post-meeting reporting, and a framework for incorporating the input from these meetings into regulatory considerations. It appropriates funds to support the program through 2030 and creates a pathway for ongoing dialogue between researchers, sponsors, patient representatives, and regulators.
At a Glance
What It Does
It creates EL–SFDD meetings convened by the Reagan-Udall Foundation and requires FDA representatives to participate in each meeting. It outlines planning, topic selection, and post-meeting reporting to inform approval and licensing decisions.
Who It Affects
FDA review staff, drug sponsors, academic researchers, patient organizations, and rare-disease advocates who participate or benefit from clearer development pathways.
Why It Matters
This mechanism aims to reduce uncertainty in rare-disease drug development by aligning on trial designs, endpoints, biomarkers, and regulatory expectations, potentially speeding safe therapies to patients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new section to the FD&C Act that creates externally led, science-focused drug development meetings (EL–SFDD). A third-party convener, the Reagan-Udall Foundation, will organize these meetings with a fixed cadence—no fewer than four per year—each targeting different rare diseases.
A permanent multistakeholder steering committee will shape meeting topics, invite medical experts and sponsors, and ensure input aligns with unmet patient needs. FDA staff will participate in these meetings to provide regulatory context and translate discussions into potential development pathways.
After each meeting, transcripts and a summary of input relevant to approval considerations must be publicly posted within 180 days, along with an assessment of how input influenced risk-benefit analyses. The act also requires annual Congress reports on meeting topics, participation, and impact on FDA workload, and it authorizes $1 million per year for 2026–2030 to support the program.
The Five Things You Need to Know
EL–SFDD meetings established to discuss rare-disease drug development, A Reagan-Udall Foundation convenes at least four meetings annually, A Science-Focused Drug Development Multistakeholder Steering Committee guides topics, Public transcripts and input summaries are posted within 180 days of meetings, Annual funding ($1M/year through 2030) supports planning, execution, and reporting
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishment and purpose of EL–SFDD meetings
This section creates externally led, science-focused meetings to tackle drug development challenges for rare diseases. It authorizes the Secretary to implement a process that brings together medical experts, sponsors, scientific organizations, and patient groups to discuss trial design, endpoints, biomarkers, and other scientific questions that affect development and approval.
Qualified third-party convenor
The Reagan-Udall Foundation is designated to convene EL–SFDD meetings. The Foundation will coordinate meeting logistics, topic selection, and stakeholder invitations, providing a neutral platform separate from FDA decision making while ensuring scientific rigor.
Minimum number of meetings
The Foundation must convene at least four EL–SFDD meetings each year, each addressing different rare diseases or groups of diseases. This cadence ensures ongoing dialogue and repeated opportunities to refine development pathways.
Steering Committee
A permanent Science-Focused Drug Development Multistakeholder Steering Committee will advise on implementation, topics, and invitations. Members include FDA representatives, academic experts, patient representatives, and industry participants, all subject to relevant conflict-of-interest policies.
Planning and stakeholder engagement
During planning, the Foundation must set objectives, draft an agenda, and compile a list of invitees. It must engage with FDA staff, the Steering Committee, industry, and patient groups to ensure broad, relevant input and alignment with unmet needs.
Post-meeting reporting
Within 180 days of a meeting, the Foundation must publish on the FDA website a transcript or recording and a summary analysis of input relevant to approval or licensing, highlighting areas of consensus, gaps in information, and next steps with FDA.
Appropriations authorization
The act authorizes $1,000,000 for each fiscal year from 2026 through 2030 to support EL–SFDD activities and allows for foundation fundraising to supplement planning and operation.
Actions following EL–SFDD meetings
Following EL–SFDD meetings, the Secretary must publicize whether input from the meeting informed a risk-benefit assessment for an approved or licensed drug and summarize how input influenced the assessment. The section also requires an annual congressional report detailing meeting topics, participation, regulatory impact, and the integration of input into future processes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Rare-disease patients and families gain clearer signals about regulatory expectations and potential development pathways through input-focused discussions and publicly available meeting outputs.
- Drug sponsors and developers benefit from clarified trial designs, endpoints, and potential flexibility considerations that can streamline development.
- Academic medical researchers gain early access to consensus-building discussions and opportunities to align scientific approaches with regulatory needs.
- FDA review divisions (CDER, CBER, CDRH) benefit from structured external input that can inform risk-benefit considerations and lifecycle planning.
- Patient advocacy organizations gain a formal channel to elevate patient perspectives in a structured, transparent process.
Who Bears the Cost
- FDA staff time and resources dedicated to participating in EL–SFDD meetings and integrating input into regulatory workflows.
- Industry sponsors and researchers bear preparation and coordination costs to contribute data, attend meetings, and align materials with expectations.
- The Reagan-Udall Foundation faces ongoing operational and funding demands to plan, execute, and report on EL–SFDD activities.
- Some stakeholders may face incremental costs to prepare for meetings and ensure alignment with evolving regulatory concepts (e.g., trial design discussions, endpoints, and biomarkers).
Key Issues
The Core Tension
The central dilemma is whether external, science-led input can meaningfully accelerate safe drug development for rare diseases while preserving regulatory agility and protecting confidential information.
The mechanism hinges on external input shaping regulatory expectations without compromising FDA’s decision-making authority. While the framework promises greater science alignment on rare-disease drug development, it also introduces potential burdens on FDA staff and sponsors from sustained, high-velocity external engagement.
Public transcripts and analyses improve transparency but raise questions about how much detail should be publicly disclosed and how to protect sensitive or proprietary information. The structure relies on careful governance to prevent conflicts of interest and to ensure that input translates into meaningful, timely regulatory actions rather than becoming a sounding-board for every stakeholder.
Finite funding and the need to balance broad stakeholder participation with efficient decision-making remain key trade-offs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.